FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2743-2746 June 30, 2005 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hadziyannis, S. J. Related Article by Lau, G. K.K. PubMed Citation

Worldwide, there are approximately 350 million carriers of hepatitis B virus (HBV), of whom half a million to 1 million die from liver disease each year. The goal of treatment for chronic hepatitis B is to prevent cirrhosis, hepatic failure, and hepatocellular carcinoma. This goal is best achieved by eradicating HBV before irreversible liver damage occurs. However, the eradication of HBV is impossible to achieve because of the presence of extrahepatic reservoirs of HBV, the integration of HBV DNA into the host genome, and the presence of an intracellular conversion pathway that replenishes the pool of transcriptional templates (covalently closed . . . [Full Text of this Article]

Source Information

From the Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor.

This article has been cited by other articles:

• Bridges, E. G., Selden, J. R., Luo, S. (2008). Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B. Antimicrob. Agents Chemother. 52: 2521-2528 [Abstract] [Full Text]  
• Zhu, Y., Curtis, M., Snow-Lampart, A., Yang, H., Delaney, W., Miller, M. D., Borroto-Esoda, K. (2007). In Vitro Drug Susceptibility Analysis of Hepatitis B Virus Clinical Quasispecies Populations. J. Clin. Microbiol. 45: 3335-3341 [Abstract] [Full Text]  
• (2005). Two More Clinical Trials of Hepatitis B Therapy. JWatch General 2005: 2-2 [Full Text]